Description
Release form
Solution for subcutaneous administration: clear or slightly opalescent, light yellow to brown with a brown tint, has a specific odor
Pharmacological action
The principle of Melsmon s action has not been fully studied, but it has been reliably established that the human placenta hydrolyzate contains biologically active substances that have an antioxidant effect, increase the activity of tissue and cellular respiration, positively affect the metabolic processes in cells, stimulate ptissue regeneration. Also, the drug reduces fatigue and activates the processes of self-regulation of the body, which helps to increase the adaptive mechanisms of the female body during premenopause and postmenopause.
Indications
According to the instructions, Melsmon is prescribed as part of complex therapy to women in peri- and postmenopausal women to correct asthenic conditions, accompanied by excessive reactivity and excitability, decreased performance and attention.
Contraindications
Arterial hypertension endocrine gland dysfunctions childhood pregnancy and lactation hypersensitivity to any component of Melsmon srdl is recommended in the following cases: weakened patient diabetes mellitus progressive cardiovascular disease renal and / or hepatic non sufficiency of gallstone disease
Use during pregnancy and lactation
Pregnancy and lactation are contraindications to the use of Melsmon.
Special instructions
The product does not contain biological stimulants – enzymes, hormones, proteins, growth factors. It is completely cleared of toxic substances, is anti-allergenic and pyrogen-free. Melsmon’s intravenous administration is strictly prohibited! Women in peri- and postmenopausal women are shown a medical examination. The doctor determines the frequency individually, but examinations should be carried out at least once every six months.
Influence on the ability to drive vehicles and complex mechanisms The components included in the preparation do not affect attention, the speed of mental and physical reactions, and therefore do not affect the ability to drive vehicles and work with complex mechanisms.
Composition
Composition 1 ampoule:
active substance: human placenta hydrolyzate * – 100 mg
additional components: benzyl alcohol (preservative) – 30 mg, sodium hydroxide – up to pH 6.8 ² 7, water for injection – up to 2 ml .
Dosage and administration
The drug Melsmon is intended exclusively for subcutaneous administration. Recommended dosage: 1 ampoule (2 ml) every other day (i.e. 3 ampoules per week). The course of therapy is 2 weeks. If necessary, the doctor recommends a second course after 1-2 weeks break.
Drug Interactions
Melsmon can be used as part of complex treatment with other drugs to treat conditions associated with peri- and postmenopausal women. their clinically relevant interactions of the facilities are not available. However, in order to avoid the development of adverse reactions is recommended to coordinate with your doctor the possibility of simultaneous use of a drug.
Overdose
No cases of overdose have been reported.
Storage conditions
Protected from light, temperature up to 25 ° C. Keep out of reach of children.
Expiration
2 years.
active substance
Plantsenty human hydrolyzate
drugstore conditions
drugstore
